iCAD Previews Fourth Quarter Financial Results, Full Report on March 28, 2023
Company is exploring strategic options for its Therapy business lineNASHUA, N.H., March 13, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD),...
Cancer
Indaptus Therapeutics Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors
NEW YORK, March 13, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company...
Oxford Population Health and SomaLogic deliver 28 million proteomic data points on China Kadoorie Biobank samples
BOULDER, Colo., March 13, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, recently completed the 7,000-plex assay...
Atavistik Bio Announces Publication in Science by Co-Founder Jared Rutter Describing Foundational Technology for its Atavistik Metabolite-Protein Screening (AMPS) Platform
MIDAS (mass spectrometry integrated with equilibrium dialysis for the discovery of allostery systematically), in-licensed and industrialized by Atavistik Bio as...
Back-to-back Studies Validate geneType Breast Cancer Risk Test
MELBOURNE, Australia, March 13, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader...
BioVie Announces the Pausing of Patient Enrollment in Ascites Phase 2b Trial, Encouraging Efficacy Data is Announced, Initiating FDA Discussions to Conduct Pivotal Registrational Trial
Patients treated with BIV201 experienced reduced ascites fluid buildup (pCARSON CITY, Nev., March 13, 2023 (GLOBE NEWSWIRE) -- BioVie Inc.,...
iCAD Announces Leadership Transition
Stacey Stevens Resigns as President and CEO and as a Member of the Board Dana Brown Named President and CEO,...
High Intra-Tumor TGF-β2 Predicts Poor Survival in Pediatric Cancer of the Brainstem
-The TGFβ1 and TGFβ3 isoforms are predictive --Validation of TGFβ2 as therapeutic target AGOURA HILLS, Calif., March 13, 2023 (GLOBE...
BioNTech to Report Full Year and Fourth Quarter 2022 Financial Results and Operational Update on March 27, 2023
MAINZ, Germany, March 13, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial...
Mersana Therapeutics Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial
CAMBRIDGE, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering...
Gracell Biotechnologies Reports Fourth Quarter and Full Year 2022 Unaudited Financial Results, and Provides Corporate Update
Plan to commence Phase 1b/2 clinical trial in US evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM)...
Alpha Tau Medical Confirms No Direct Exposure to Silicon Valley Bank
JERUSALEM, March 12, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the...
Agenus Schedules Conference Call to Discuss the Company’s Minority Cash Holdings at SVB
Conference Call on Monday, March 13, 2023 at 8:30 a.m. ETLEXINGTON, Mass., March 11, 2023 (GLOBE NEWSWIRE) -- Agenus (Nasdaq:...
Tango Therapeutics Announces Limited Exposure to Silicon Valley Bank
BOSTON, March 10, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and...
Mersana Therapeutics Provides Statement About SVB
CAMBRIDGE, Mass., March 10, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering...
Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank
SAN DIEGO and TORONTO, March 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO; TSX:...
Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck Oncology
MALVERN, Pa., March 10, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing...
Enterome’s Management to Attend Upcoming Meetings
Paris, France – March 10, 2023 Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer and inflammatory diseases based...
Predictive Oncology Issues Letter to Shareholders
Signature of Raymond F. Vennare, Chief Executive Officer Signature of Raymond F. Vennare, Chief Executive OfficerEAGAN, Minn., March 09, 2023...
Qualigen Therapeutics Presents Data on its RAS Inhibitor Program at the American Association for Cancer Research: Targeting RAS Conference
Qualigen Therapeutics, Inc. F3 Compounds Cooperate with Checkpoint Inhibitors and Other RAS Inhibitors Qualigen Therapeutics, Inc. F3-8-60 inhibits RAS RAF...